Schrodinger (NASDAQ:SDGR) versus Movano (NASDAQ:MOVE) Critical Contrast

Schrodinger (NASDAQ:SDGR) and Movano (NASDAQ:MOVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Schrodinger and Movano, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1	4	4	0	2.33
Movano	1	0	0	0	1.00

Schrodinger currently has a consensus price target of $20.25, suggesting a potential upside of 53.06%. Given Schrodinger’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Schrodinger is more favorable than Movano.

Volatility & Risk

Schrodinger has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 16.6% of Movano shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 10.4% of Movano shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Schrodinger and Movano’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Movano	-2,462.55%	-647.91%	-11.69%

Earnings & Valuation

This table compares Schrodinger and Movano”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87 million	3.82	-$103.26 million	($1.41)	-9.38
Movano	$430,000.00	64.28	-$18.28 million	($10.61)	-2.31

Movano has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.

Summary

Schrodinger beats Movano on 9 of the 14 factors compared between the two stocks.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.